Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Abrignani

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
European Journal of Immunology|June 1, 1997
Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4O Finco, S Nuti, M T De Magistris, et al.
European Journal of Immunology|March 10, 2001
Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infectionC Prezzi, M A Casciaro, V Francavilla, et al.
The Journal of Infectious Diseases|February 1, 1991
Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccineJ Wintsch, C L Chaignat, D G Braun, et al.
Science (New York, N.Y.)|October 30, 1998
Binding of hepatitis C virus to CD81P Pileri, Y Uematsu, S Campagnoli, et al.
Virology|September 7, 2001
Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant FabsR Burioni, F Bugli, N Mancini, et al.
Hepatology (Baltimore, Md.)|September 10, 1998
Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragmentsR Burioni, P Plaisant, A Manzin, et al.
Hepatology (Baltimore, Md.)|October 2, 1998
High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis CK Ishii, D Rosa, Y Watanabe, et al.
AIDS Patient Care and Stds|October 8, 2004
Sexual transmission of hepatitis C virus and prevention with intramuscular immunoglobulinM Piazza, L Sagliocca, G Tosone, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Prophylaxis of hepatitis C with intramuscular immunoglobulin: clinical and economic appraisalM Piazza, L Sagliocca, G Tosone, et al.
Journal of Virology|April 25, 2000
Structure-function analysis of hepatitis C virus envelope-CD81 bindingR Petracca, F Falugi, G Galli, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
European Journal of Immunology|June 1, 1997
Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4O Finco, S Nuti, M T De Magistris, et al.
European Journal of Immunology|March 10, 2001
Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infectionC Prezzi, M A Casciaro, V Francavilla, et al.
The Journal of Infectious Diseases|February 1, 1991
Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccineJ Wintsch, C L Chaignat, D G Braun, et al.
Science (New York, N.Y.)|October 30, 1998
Binding of hepatitis C virus to CD81P Pileri, Y Uematsu, S Campagnoli, et al.
Virology|September 7, 2001
Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant FabsR Burioni, F Bugli, N Mancini, et al.
Hepatology (Baltimore, Md.)|September 10, 1998
Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragmentsR Burioni, P Plaisant, A Manzin, et al.
Hepatology (Baltimore, Md.)|October 2, 1998
High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis CK Ishii, D Rosa, Y Watanabe, et al.
AIDS Patient Care and Stds|October 8, 2004
Sexual transmission of hepatitis C virus and prevention with intramuscular immunoglobulinM Piazza, L Sagliocca, G Tosone, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Prophylaxis of hepatitis C with intramuscular immunoglobulin: clinical and economic appraisalM Piazza, L Sagliocca, G Tosone, et al.
Journal of Virology|April 25, 2000
Structure-function analysis of hepatitis C virus envelope-CD81 bindingR Petracca, F Falugi, G Galli, et al.
Pageof 6